News

For the most recent news and press releases, visit our investor relations website: www.ir.icecure-medical.com

IceCure Medical Announces New Independent Data Published in the Journal of Cancer Therapy Showing that Percutaneous Cryoablation Presents a Potential Substitute for Lumpectomy for Tumors <15mm using ProSense™

CAESAREA, Israel, November 1, 2021 — IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) (“IceCure” or the “Company”), developer of the next generation minimally invasive cryoablation technology that destroys tumors by freezing, today announced that a peer reviewed article titled, “VAB and MRI Following Percutaneous Ultra-Sound Guided Cryoablation for Primary Early-Stage Breast Cancer: A Pilot Study in Japan,” was published in the Journal of Cancer Therapy by lead author Dr. Hisanori Kawamoto, MD, PhD. from the Department of Breast Surgery Breast and Imaging Center, St. Marianna University School of Medicine, Japan.

Read More »

What a fantastic #NCoBC2023! Thank you to everyone who stopped by @IceCureMedical’s booth to learn more about #cryoablation for breast tumors with the #ProSense System.

See you next year!

#breastcare #WomensHealth @NCBC_BreastCare

Thank you for 1,000 #Twitter followers! @IceCureMedical is so grateful for every one of you.
We appreciate your support of our #LiquidNitrogen Based #ProSense #Cryoablation #Sytem for optimal tumor destruction.

#interventionalradiology #interventionaloncology #medtwitter

למה אייסקיור הייתה בשבוע האופנה #TLVFashionWeek?

טללית בוסי תל צור שלנו דיברה בפאנל פתרונות בסרטן השד כדי לשתף כיצד מערכת הפרוסנס שלנו משנה את הדרך בה אנו מטפלים במחלה בישראל על ידי קריואבלציה.

לסרטון המלא: http://youtu.be/MThCqWlHVlc

@IceCureMedical @BussiTlalit

Read all about @IceCureMedical 's @BussiTlalit's insights on our participation in #TLVFashionWeek's #BreastCancer panel in this article by @NoCamels!

https://nocamels.com/2023/03/tlv-fashion-week-showcases-breast-cancer-freezing-tech/?fbclid=IwAR2lD0uf2LEMJa-vYIG6Ynvdb7YoQE0yEG2RrMzEdc8mEhnHGYecb99NlfE

IceCure Medical Announces New Independent Data Published in the Journal of Cancer Therapy Showing that Percutaneous Cryoablation Presents a Potential Substitute for Lumpectomy for Tumors <15mm using ProSense™

CAESAREA, Israel, November 1, 2021 — IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) (“IceCure” or the “Company”), developer of the next generation minimally invasive cryoablation technology that destroys tumors by freezing, today announced that a peer reviewed article titled, “VAB and MRI Following Percutaneous Ultra-Sound Guided Cryoablation for Primary Early-Stage Breast Cancer: A Pilot Study in Japan,” was published in the Journal of Cancer Therapy by lead author Dr. Hisanori Kawamoto, MD, PhD. from the Department of Breast Surgery Breast and Imaging Center, St. Marianna University School of Medicine, Japan.

Read More »